Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Semaglutide (Wegovy) does not directly attack hair follicles, but rapid weight loss, reduced calorie and protein intake, and dips in iron, ferritin, vitamin D, or zinc can push follicles into telogen effluvium, a temporary shedding phase that often shows first at the crown and part line. For Black women, this shedding can unmask or accelerate central centrifugal cicatricial alopecia (CCCA) or traction alopecia, conditions where inflammation and scarring can make thinning permanent if it is not addressed early. Protective strategies include a slower rate of weight loss, higher daily protein, lab testing for nutrient deficiencies, low-tension styling, and gentle scalp care, and there are several timing and diagnostic details worth reviewing below before you assume the loss is only from the medication. Most G
How Black Women Can Protect Their Hair Density on GLP-1s
Wegovy (semaglutide) is a GLP-1 receptor agonist approved for weight management. It works by slowing gastric emptying, reducing appetite, and promoting a feeling of fullness. As more Black women turn to GLP-1 medications for safe, effective weight loss, questions arise about potential side effects—particularly hair thinning.
In most cases, shedding from telogen effluvium appears 2–4 months after the trigger and resolves within 6–12 months, once the body adapts.
Black hair has unique structural and care considerations:
When weight loss–related shedding overlaps with existing breakage risks, volume loss becomes more noticeable—especially around the crown and edges.
Be proactive. Monitor your hair health and note changes such as:
If you spot these signs, don’t panic—telogen effluvium is usually reversible. Still, it’s wise to track your symptoms and act early.
Nutritional support is key to minimizing shedding and encouraging regrowth:
Consider a multivitamin or a targeted hair supplement if dietary intake is limited—but consult your doctor first.
Reducing mechanical stress helps preserve density:
Improving circulation can support hair follicles:
Chronic stress can exacerbate hair shedding:
It’s smart to monitor your overall health and any new symptoms while on Wegovy. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to see if your shedding pattern fits telogen effluvium or another condition.
Try the Ubie Symptom Checker for free →
Hair shedding tied to weight loss usually self-resolves. However, reach out to a healthcare professional if you experience:
Only a medical evaluation can rule out conditions like alopecia areata, thyroid disorders, or anemia.
Your hair’s health is an important part of your well-being. With the right diet, care routine, and medical guidance, you can support your crown’s density even as you achieve your weight-loss goals on Wegovy.
(References)
* Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. J Am Acad Dermatol. 2024 Jul;91(1):166-168. doi: 10.1016/j.jaad.2024.03.021. Epub 2024 Mar 29. PMID: 38554940.
* Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, Lo Sicco KI. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024 Sep;63(9):1128-1130. doi: 10.1111/ijd.17246. Epub 2024 May 13. PMID: 38741261.
* Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e153-e154. doi: 10.1111/jdv.20197. Epub 2024 Jun 24. PMID: 38925559.
* Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May;92(5):1141-1143. doi: 10.1016/j.jaad.2025.01.046. Epub 2025 Jan 23. PMID: 39863171.
* Rojas Lopez RF, Lynett Barrera D, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025 Aug;17(8):e90021. doi: 10.7759/cureus.90021. Epub 2025 Aug 13. PMID: 40951222; PMCID: PMC12431796.
* Tassavor B, Al Salem S. Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review. Cureus. 2025 Sep;17(9):e93282. doi: 10.7759/cureus.93282. Epub 2025 Sep 26. PMID: 41020015; PMCID: PMC12466318.
* Camino-Salvador JM, Rodríguez-Cuadrado FJ, Pinto-Pulido EL, Fernández-Parrado M. Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern. J Eur Acad Dermatol Venereol. 2026 May;40(5):e321-e323. doi: 10.1111/jdv.70088. Epub 2025 Sep 30. PMID: 41025593.
* Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disord. 2025 Oct;11(5):416-423. doi: 10.1159/000544023. Epub 2025 Feb 14. PMID: 41058954; PMCID: PMC12500303.
* Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep;17(9):e92454. doi: 10.7759/cureus.92454. Epub 2025 Sep 16. PMID: 41111833; PMCID: PMC12530271.
* Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026 Apr-Jun;109(2):368504261444578. doi: 10.1177/00368504261444578. Epub 2026 Apr 17. PMID: 41998799; PMCID: PMC13100445.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.